GlassScriptPhysician profile
Matthew Auyoung
NPI 1053707190
$10,503.50
in general payments reported to CMS, 2019-2025
34 companies · $3,628 in 2025
The $3,628 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $957 · 2020: $678 · 2021: $751 · 2022: $722 · 2023: $1,845 · 2024: $1,923 · 2025: $3,628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,221 · Travel and Lodging: $1,154 · Education: $21.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,220.57 |
| Travel and Lodging | $1,154.22 |
| Education | $21.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $2,266.01 | 2023-2025 | Amvia Edge, Biomonitor, Acticor 7 Vr-T Dx |
| Novartis Pharmaceuticals Corporation | $1,187.80 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $815.64 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $628.71 | 2019-2025 | Farxiga, Wainua |
| Amgen INC. | $589.60 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $551.08 | 2022-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $382.96 | 2023-2025 | |
| Pfizer INC. | $349.69 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $348.29 | 2023-2025 | Verquvo, Belsomra, Lagevrio |
| Impulse Dynamics (USA) INC. | $304.31 | 2022-2023 | Optimizer |
| Edwards Lifesciences Corporation | $301.43 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| E.R. Squibb & Sons, L.L.C. | $261.40 | 2022-2025 | Camzyos, Eliquis |
| Chiesi USA, INC. | $239.66 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $233.93 | 2022-2024 | Xarelto |
| Esperion Therapeutics, INC. | $191.98 | 2021-2025 | Nexletol |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $191.29 | 2019 | |
| Novo Nordisk INC | $165.63 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Medtronic, INC. | $162.24 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $143.67 | 2019 | |
| Boston Scientific Corporation | $139.44 | 2024-2025 | Emblem Mri S-Icd, Watchman Flx, Bodyguardian |
| Philips North America LLC | $128.18 | 2023-2024 | (5044) Mcot |
| Sanofi-Aventis U.S. LLC | $124.16 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $124.02 | 2022 | |
| Abbott Laboratories | $120.57 | 2019-2022 | |
| Lundbeck LLC | $113.36 | 2020-2021 | |
| Glaxosmithkline, LLC. | $94.83 | 2025 | Shingrix, Bexsero |
| Baxter Healthcare | $90.21 | 2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Lilly USA, LLC | $56.93 | 2024 | Jardiance |
| Irhythm Technologies, INC. | $54.49 | 2022-2023 | Zio Xt Patch |
| Atricure, INC. | $41.08 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $38.47 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $24.98 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $24.04 | 2024 | |
| Alnylam Pharmaceuticals INC. | $13.42 | 2024 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Auyoung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.